R&D Projects


Predictive system for assessing response to platinum-derived treatment in lung cancer

The mainstay of treatment for non-small-cell lung cancer (NSCLC) is resection surgery, although this is not always possible. Platinum-based chemotherapy, with or without maintenance therapy and followed by second-line cytotoxic chemotherapy, is the standard treatment for most patients with advanced NSCLC, with an average survival rate of around one year.

Over the last 30 years, a large number of studies have focused on gaining insight into the molecular mechanisms that explain the cisplatin-resistant phenotype (CDDP) of tumour cells, which could provide crucial information for the resensitisation of treatment. This project emerges as a consequence of the data previously obtained by two research groups belonging to the IdiPAZ and IRYCIS Health Research Institutes, which combined their efforts in the selection of aptamers against the MAFG transcription factor as a prognostic marker of resistance to chemotherapeutic drugs in relation to lung cancer.

30 years

of research on lung cancer resistance to NSCLC


Platinum-based chemotherapy is the standard treatment for most patients with advanced lung cancer.

Both groups have carried out studies linking the regulation of the gene encoding the MAFG1 protein to the response to cisplatin chemotherapy in NSCLC, proposing this as a potential new therapeutic target for cisplatin-resistant tumours of this type.

Together with the companies Aptus and Atrys, the consortium’s main aim is to use the MAFG transcription factor as a predictive marker of the response to treatment with platinum derivatives by developing aptamer-based prognostic tools. To this end, the aim is to develop two prognostic kits, based on aptahistochemistry and liquid biopsy for the determination of MAFG marker levels as a prognostic marker of resistance to platinum derivatives in lung cancer patients.

To achieve the objectives

Expediente: RTC2019-007229-1 2020-2023

This project is led by Aptus SL and has the collaboration of the Biomedical Research Foundation of the Hospital Ramón y Cajal (FIBio-HRC), the Biomedical Research Foundation of the La Paz University Hospital (FIBHULP), and Atrys Health SA.

It has been funded by the Ministry of Science, Innovation and Universities within the CHALLENGES-COLLABORATION Sub-programme, 2019 Call, and by the European Union, with the aim of promoting technological development, innovation, and quality research.

Financial backers

Related projects